Self-assembling, self-adjuvanting and fully synthetic peptide nanovaccine for cancer immunotherapy
Author:
Funder
National Natural Science Foundation of China
Fundamental Research Funds for the Central Universities
Publisher
Elsevier BV
Subject
Biomedical Engineering,Biomaterials,Bioengineering
Reference142 articles.
1. PROVENGE (Sipuleucel-T) in prostate cancer: the first FDA-approved therapeutic cancer vaccine;Cheever;Clin. Cancer Res.,2011
2. Phase I immunotherapeutic trial with long peptides spanning the E6 and E7 sequences of high-risk human papillomavirus 16 in end-stage cervical cancer patients shows low toxicity and robust immunogenicity;Kenter;Clin. Cancer Res.,2008
3. Combined clinical trial results of a HER2/neu (E75) vaccine for the prevention of recurrence in high-risk breast cancer patients: U.S. military cancer institute clinical trials group study I-01 and I-02;Peoples;Clin. Cancer Res.,2008
4. Phase II clinical trial of multiple peptide vaccination for advanced head and neck cancer patients revealed induction of immune responses and improved OS;Yoshitake;Clin. Cancer Res.,2015
5. Therapeutic vaccines for cancer: an overview of clinical trials;Melero;Nat. Rev. Clin. Oncol.,2014
Cited by 14 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Inhibition of platelet adhesion to exposed subendothelial collagen by steric hindrance with blocking peptide nanoparticles;Colloids and Surfaces B: Biointerfaces;2024-05
2. Glutathione Depletion‐Induced Versatile Nanomedicine for Potentiating the Ferroptosis to Overcome Solid Tumor Radioresistance and Enhance Immunotherapy;Advanced Healthcare Materials;2024-02-11
3. Advances in Cancer Vaccine Research;ACS Biomaterials Science & Engineering;2023-11-03
4. Progressing nanotechnology to improve targeted cancer treatment: overcoming hurdles in its clinical implementation;Molecular Cancer;2023-10-09
5. Improving the efficacy of peptide vaccines in cancer immunotherapy;International Immunopharmacology;2023-10
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3